NCT00929162 - ZD4054 (Zibotentan) or Placebo Plus Chemotherapy in Patients With Advanced Ovarian Cancer | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2011

Conditions

Patients With Advanced Ovarian Cancer Sensitive to Platinum-based Chemotherapy

Interventions

DRUG

ZD4054 Zibotentan

10 mg oral tablets once daily

DRUG

Paclitaxel

175mg/m2 IV on day 1 every 3 weeks

DRUG

Carboplatin

Carboplatin AUC of 5.0 IV on day 1 every 3 weeks

DRUG

Placebo

matching placebo for ZD4054 10 mg

Trial Locations (20)

Research Site, Berlin

Research Site, Dresden

Research Site, Düsseldorf

Research Site, Essen

Research Site, Karlsruhe

Research Site, Kassel

Research Site, Kiel

Research Site, Lich

Research Site, Magdeburg

Research Site, Marburg

Research Site, München

Research Site, Rostock

Research Site, Wiesbaden

Research Site, Milan

Research Site, Perugia

Research Site, Aviano

Research Site, Roma

Research Site, Campobasso

Research Site, Modena

Research Site, Napoli